Examining the Treatment Landscape of Metastatic NSCLC Expressing the Targetable Mutations RET, MET, and KRAS | PTCE Pharmacy Connect

Educational Objectives • Review the targetable mutations RET, MET, and KRAS, including associated agents for the treatment of metastatic non-small cell lung cancer (NSCLC) • Discuss the ways a pharmacist may improve adherence, toxicity management, and outcomes for patients with metastatic NSCLC expressing RET, MET, and KRAS mutations   Josiah D. Land, PharmD, BCOP Clinical Pharmacy Specialist – Thoracic Medical Oncology Department of Pharmacy Memorial Sloan Kettering Cancer Center New York, New York   Josiah D. Land, PharmD, BCOP, has the following financial relationship with a commercial interest to disclose: Consultant (advisory board): Bristol Myers Squibb   Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hours (0.05 CEU) under the ACPE universal activity number0290-0000-22-388-H01-P. The activity is available for CE credit through July 29, 2023.   This activity is supported by educational funding provided by Amgen. Learn more about your ad choices. Visit megaphone.fm/adchoices